Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
The LAMEA Continuous Glucose Monitoring Systems Market is expected to grow at a CAGR of 34.2% during 2016 -2022. The increased and ongoing efforts of ?patient-education? and ?screening for diabetes? programs would increase the awareness levels and eventually would drive the overall diabetes treatment and management market growth. Significantly growing purchasing power among the end-userpatient base in the developing and underdeveloped regions would act as a major factor driving the market during the forecast period. The CGMS devices have witnessed continuous technological evolution CGMS with smartphone connectivity. Wearable CGMS is another promising product with tremendous potential within the wearable healthcare devices. Non-invasive CGMS such as Symphony CGM System, due to its user-friendliness, extensive applications and FDA approvals for the same, have gained prominence over the years. Bionic pancreas is another notable product which is a smart and a complete diabetes management solution which is majorly used for Type I diabetes patients, is another notable breakthrough within the CGMS market.
The report highlights the adoption of Continuous Glucose Monitoring Systems in LAMEA. Based on the Component, the LAMEA Continuous Glucose Monitoring Systems Market is segmented into Sensors, Transmitters & Receivers and Integrated Insulin pumps segment. Based on the End user, the market is bifurcated into Diagnostic centersclinics, ICUs and Home Healthcare segments.
The countries included in the report are Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria and Rest of LAMEA. Key Players profiled in the report includes Roche Diagnostics, Abbott Laboratories, Dexcom Inc., Novo Nordisk, Ypsomed AG, GlySens Incorporated, Medtronic Plc and Johnson & Johnson.